Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ivermectin + brimonidine is a topical combination drug used in the treatment of rosacea, specifically targeting persistent erythema and inflammatory papulopustular lesions[1][2][4][5][7]. - Ivermectin is an anti-parasitic and anti-inflammatory small molecule that targets Demodex mites and inflammatory pathways, reducing papules and pustules. - Brimonidine is a selective alpha-2 adrenergic receptor agonist that causes vasoconstriction, thereby decreasing cutaneous microvascular blood flow and reducing persistent facial erythema. Combined use leverages both anti-inflammatory and vasoconstrictive mechanisms for improved efficacy compared to monotherapy, as supported by randomized controlled trials. Research supports the combination's superior effectiveness and safety profile for mild to moderate and moderate to severe rosacea[1][2][3][4][5]. The combination is available as two separate products applied simultaneously (ivermectin cream and brimonidine gel) and has also been formulated experimentally as a single topical cream[2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ivermectin + brimonidine.